2Francesca Di Fabio,Carmine Pinto,Fabiola L. Rojas Llimpe,Stefano Fanti,Paolo Castellucci,Ciro Longobardi,Vita Mutri,Chiara Funaioli,Francesca Sperandi,Stefania Giaquinta,Andrea A. Martoni.The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab[J]. Gastric Cancer . 2007 (4)
3Chen W,Delaloye S,Silverman DH,et al.Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with fluorothymidine positron emission tomography:a pilot study. Journal of Clinical Oncology . 2007
4McNeil C.K-Ras mutations are changing practice in advanced colorectal cancer. Journal of the National Cancer Institute . 2008
5Cancello G,Montagna E,D’Agostino D,et al.Continuing trastu-zumab beyond disease progression:outcomes analysis in patients withmetastatic breast cancer. Breast Cancer Research . 2008
6Rocha-Lima CM,Soares HP,Raez LE,et al.EGFR tar-geting of solid tumors. Cancer Control . 2007
7DY Hallaert,A Jaspers,CJ Noesel,MH Oers,AP Kater,E Eldering.c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood . 2008
8Padera, T. P,B. R. Stoll,J. B. Tooredman,D. Capen,E. di Tomaso, et al."Pathology:cancer cells compress intratumour vessels.". Nature . 2004
9Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research . 2004
10Shah MA,Ramanathan RK,Ilson DH,et al.Multicenter phaseⅡstudy of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology . 2006
二级参考文献15
1Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-selfcytotoxic T lymphocytes by recombinant adeno-associated virusbased gene loading of dendritic cells [ J ]. Cancer Gene Ther,2005,12(3) :304 - 312.
2Midgley R, Kerr DJ, Mirza N, et al. A phase Ⅱ dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [J]. Proc Am Soc Clin Oncol,2002,21:23b.
3Chang JWC,Hsieh JJ,Chen J S, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma [ J ]. ProcAm Soc Clin Oncol,2002,21:3b.
4Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells[J ]. Eur J Immunol, 2002,32(1) :30 - 38.
5Slichenmyer WJ,Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases[J]. Semin Oncol, 2001,28 (Suppl 16) :S67 - S79.
6Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as firstline and maintenance therapy for patients with indolent nonhodgkin's lymphoma[J]. J Clin Oncol,2002,20(20):4261 -4267.
7Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer[J]. Clin Colorectal Cancer ,2003,2(4): 246 - 251.
8Goodman L. Persistance-luck-Avastin[J]. J Clin Invest,2004, 113(7) :934 - 940.
9Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastro-intestinal stromal tumors (GIST), an EORTC phase Ⅰ study[J]. Proc Am Soc Clin Oncol,2001,20 : 1 a.
10Fukuora M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839(Iressa) for patients with advanced non-smallcell lung cancer ( IDEAL. 1 ) [ J ]. Proc Am Soc Clin Oncol, 2003,22: 298a.
8Gjomarkaj M, Pace E, Meils M, et al. Dendritic cells with a potent accessory activity are present in human exudative malignant pleural effusions[J]. Eur Respir J, 1997,10(3) : 592 -597.
9Suzuki Y, Yanagawa H,Nishioka Y,et al. Efficient generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes in patients with lung eancer [J]. Lung Cancer, 2001,34(2) : 195-205.
10Ma Y, Aymeric 1., Locher C, et al. The dendritic cell-tumor cross-talk in cancer[J]. Curr ()pin Immunol,2011,23(1) : 146 -152.
